business / news / / The Boston Globe
Eli Lilly & Co. will buy Kelonia Therapeutics for at least $3.25 billion.
Eli Lilly will acquire Kelonia Therapeutics for $3.25 billion, with milestones increasing total up to $7 billion.
KEY POINTS
- Kelonia's KLN-1010 therapy genetically modifies immune cells inside the body for blood cancer treatment.
- This acquisition is Lilly's third Massachusetts biotech purchase in 2024, following Orna and Centessa deals.
- Lilly's recent partnerships and acquisitions focus on cell therapies that do not require cell removal.
COMPANIES
Summarized by Newsio from The Boston Globe. How we summarize →